Migraine Drug Gains in Test, and Shares in Its Maker Soar
Wednesday, May 27, 2009 - 00:00
in Psychology & Sociology
Shares of MAP Pharmaceuticals rose 186 percent to $9 as its Levadex drug cleared a late-stage clinical test.
Shares of MAP Pharmaceuticals rose 186 percent to $9 as its Levadex drug cleared a late-stage clinical test.
